A conversation with Adriane Fugh-Berman, MD, Associate Professor at Georgetown University Medical Center and Director of PharmedOut. We discuss how the marketing of Androgel uses symptom quizzes to convince men and physicians that "low testoste

The Forgotten eHealth Code of Ethics

Jun 22nd, 2017 4m 12s

Any research or effort designed to improve the quality of health information on the Internet must build upon the work already done by the creators of the international eHealth Code of Ethics, which is as relevant today as it was back in 2000.

AMA Struggles to Reign in Consumer Drug Ads

Jun 15th, 2017 4m 33s

You have to give kudos to the good doctors and policy makers of the American Medical Association for trying over the course of many to ban or in some way curtail direct-to-consumer drug ads by pharmaceutical companies. The latest effort focuses

Counter Detailing Offers Redemption But Little Hope of Success

Jun 12th, 2017 4m 28s

Do you hate your job in pharma? Perhaps, like a friend of mine, your position got eliminated after many years of loyal service. But it may be a blessing in disguise if the behavior of Big Pharma is more and more at odds with your personal value

Patient Centricity & Pharma’s Reputation

Jun 1st, 2017 3m 42s

Patient Centricity used to be a buzzword in that it was often mentioned but seldom practiced by pharma companies. A lot of progress has been made in the past years to achieve patient centricity, but not all drug companies have had much success.

The Two Faces of FDA Regarding the Opioid Epidemic

May 25th, 2017 3m 51s

The #FDA has a lot of hurdles to overcome in its effort to stem the #opioid crisis it helped to create. And it doesn’t help that Trump’s proposed Medicaid cuts will negatively impact funding for drug rehab treatment.

The Coming Digital Transformation of Pharma Marketing

May 18th, 2017 7m 23s

Many pharmaceutical companies are operating well-established business processes that are not optimized for the digital era. This is leading to inefficiencies and missed opportunities. Arno Sosna, General Manager of Commercial Products at Veeva

Big Pharma Struggles to Distance Itself from “Price Gouging” Small Pharma

May 12th, 2017 4m 39s

The drug industry is reeling from criticism about drug prices coming from all sides and especially from the president of the United States. First it tried public relations and CEO speaking tours. When that didn’t work it took more drastic actio

The Benefits and Risks of Limiting Pharma Sales Rep Access to Physicians

May 4th, 2017 6m 24s

Pharmaceutical sales representatives are faced with increasingly limited access to physicians as many academic medical centers and other healthcare centers adopt conflict of interest policies restricting detailing. This is another benefit versu

The Digital Gap Between Pharma and Other Industries

Apr 28th, 2017 2m

Brain Fox, Senior Partner at McKinsey, talks about how the pharma industry lags other industries in its investment in digital technology and in testing the effectiveness of its digital marketing campaigns.

The Internet of Things -> Better Health Outcomes -> Better Adherence -> More Profits

Apr 24th, 2017 2m 35s

While attending an eyeforpharma Philadelphia conference, Pharmaguy interviewed Jeff Usewick, Director for Healthcare Business Development at SoftServe, about how the drug industry should focus on using Internet of Things technology to improve h

Why I March For Science

Apr 21st, 2017 2m 49s

This is the speech I intend to make at the March for Science in Doylestown PA on April 22, 2017.

Drug Approval Speed Versus Drug Safety

Apr 18th, 2017 3m 34s

More user fees paid to the FDA by the drug industry and the push for less rigorous scientific proof in clinical trials may lead to faster drug approvals, but also more deaths due to side effects. Where’s the balance between speed and safety?

“Patient Centricity” Finally Pays Off for Pharma

Apr 11th, 2017 3m 21s

“Patient Centricity” is finally paying off for drug companies in a BIG way, but it has nothing to do with designing more effective clinical trials or better marketing. It has everything to do with influencing lawmakers and especially the FDA.

Gottlieb's Views on Drug Safety Versus Speed to Market

Apr 6th, 2017 3m 45s

Where’s the balance between drug safety and speeding up clinical trials to bring drugs to market faster? That was a major issue underscoring the testimony of Dr. Scott Gottlieb, president Trump’s nominee to head the FDA, before the U.S. Senate

Warren Goes After Gottlieb Regarding Drug Safety

Apr 6th, 2017 4m 54s

Senator Elizabeth Warren of Massachusetts challenged Dr. Scott Gottlieb about his views of FDA's drug review process at Gottlieb's April 5, 2017, confirmation hearing before the U.S. Senate Committee on Health, Education, & Pensions.

Dr. Gottlieb's Comments on Opioid Epidemic

Apr 5th, 2017 8m 47s

At his April 5, 2017, Senate Hearing, Dr. Scott Gottlieb, President Trump's nominee for FDA Commissioner, answered questions about the opioid epidemic by Sen. Tim Kaine, Sen. Michael Bennet, and Sen. Al Franken.

Making Sense of DTC Ad Spending: Patients vs TV vs Digital

Apr 4th, 2017 6m 3s

Data about how much money the U.S. pharmaceutical industry spends on promoting drugs to consumers come from several sources, which often report different numbers. That makes it difficult to ferret out what portion of the total is spend on TV an

Rate